重组人EPO联合神经节苷酯钠治疗急性重症颅脑损伤的临床效果

目的研究重组人促红细胞生成素(EPO)联合神经节苷酯钠治疗急性重症颅脑损伤的效果。方法采用抽签法将67例急性重症颅脑损伤患者分为观察组(34例)和对照组(33例)。对照组静脉滴注神经节苷酯钠注射液,观察组联合皮下注射重组人EPO。比较两组的治疗效果。结果治疗后,两组的血清S100B、Tau、NSE、GFAP水平均降低,且观察组低于对照组,差异具有统计学意义(P<0.05)。治疗后,两组血清IL-2、sICAM-1、P-选择素水平均降低,且观察组低于对照组,差异具有统计学意义(P<0.05)。治疗后,两组的血清AOPP、LPO、8-iso-PGF2α水平均降低,且观察组低于对照组,差异具有统计学意义(P<0.05)。结论重组人EPO联合神经节苷酯钠能改善急性重症颅脑损伤患者的炎症反应、神经损伤、氧化应激反应。

Clinical effect of recombinant human EPO combined with ganglioside sodium in the treatment of acute severe craniocerebral injury

Objective To study the effect of recombinant human erythropoietin(EPO)combined with ganglioside sodium in the treatment of acute severe craniocerebral injury.Methods A total of 67 patients with acute severe craniocerebral injury were divided into observation group(34 cases)and control group(33 cases)by drawing lots method.The control group was intravenously infused with ganglioside sodium injection,the observation group was combined with recombinant human EPO subcutaneously injection.The therapeutic effects of the two groups were compared.Results After treatment,serum S100B,Tau,NSE and GFAP levels in the two groups decreased,and those in the observation group were lower than the control group,the differences were statistically significant(P<0.05).After treatment,the serum IL-2,sICAM-1 and P-selectin levels in the two groups decreased,and those in the observation group were lower than the control group,the differences were statistically significant(P<0.05).After treatment,the serum AOPP,LPO and 8-iso-PGF2αlevels in the two groups decreased,and those in the observation group were lower than the control group,the differences were statistically significant(P<0.05).Conclusion Recombinant human EPO combined with ganglioside sodium can improve the inflammatory response,nerve injury and oxidative stress response in patients with acute severe craniocerebral injury.